In a landmark move for global public health, the World Health Organization (WHO) has officially endorsed lenacapavir—a twice-yearly injectable—as part of its HIV prevention toolkit. This recommendation marks a significant advancement in the fight against HIV, particularly for communities with the greatest need for accessible, long-acting prevention solutions.
WHO’s Bold Stance
On July 14, 2025, the WHO updated its global guidelines to include lenacapavir as a recommended pre-exposure prophylaxis (PrEP) option. This decision underscores the organization’s commitment to evolving HIV prevention strategies in line with the latest scientific evidence and patient needs. With its long-acting formulation, lenacapavir offers a revolutionary alternative to daily oral PrEP, promising greater convenience, adherence, and privacy.
Leading global media outlets, including Reuters, CBS News, The Economic Times, and Pharmacy Times, have spotlighted this announcement, recognizing its potential to reshape HIV prevention landscapes across diverse populations and regions.
Empowerment Through Access
WHO’s endorsement is more than symbolic. It activates practical mechanisms for global distribution and uptake. Lenacapavir is now eligible for WHO prequalification, enabling donor-backed procurement through major public health funding channels such as PEPFAR, the Global Fund, and national health ministries. This means that the medication could soon be available at scale, especially in low- and middle-income countries where access to daily PrEP has often been limited.
By placing lenacapavir on the global stage, WHO is driving a shift from aspiration to access—ensuring that biomedical innovation translates into real-world protection.
Who Wins Big
Certain populations stand to gain most from this new PrEP option. Communities historically marginalized in health systems—including transgender individuals, sex workers, people who inject drugs, and adolescent girls and young women—will benefit from the injectable’s discretion, long-acting protection, and reduced need for frequent clinic visits.
According to the JAMA Network, these groups often face higher barriers to daily oral PrEP adherence due to stigma, unstable housing, or limited healthcare access. A twice-yearly injection can sidestep many of these challenges, offering a dignified and empowering alternative.
Wrap-Up
From Kigali to Bangkok, from Johannesburg to New York, injectable PrEP represents more than just a technological breakthrough—it is a form of liberation. With WHO’s global backing, lenacapavir has the potential to turn the tide in HIV prevention, particularly for those who need it most.
As this innovation makes its way into clinics and communities worldwide, the hope is clear: a future where prevention is not only possible but practical, empowering, and inclusive.
More Blogs